What is the FDG PET-CT avidity of various tumor sites?

FDG PET-CT Avidity of Various Tumor Sites

FDG PET-CT demonstrates variable avidity across different tumor types, with lymphomas, lung cancers, and most solid tumors showing high uptake, while certain histologic subtypes including mucinous adenocarcinomas, bronchoalveolar carcinomas, hepatocellular carcinomas, and signet ring cell carcinomas characteristically show low or absent FDG avidity.

High FDG-Avid Tumors

Lymphomas

• Aggressive non-Hodgkin lymphomas (including DLBCL): Consistently highly FDG-avid 1
• Follicular lymphomas (grade 1-3a): FDG-avid, suitable for PET-CT staging 1
• Hodgkin lymphoma: Typically FDG-avid at baseline 2

Lung Cancers

• Non-small cell lung cancer (NSCLC): Overall sensitivity 96% for FDG uptake in lesions >1 cm 3
• Most adenocarcinomas and squamous cell carcinomas: Highly FDG-avid 4
• Higher standardized uptake values correlate with more aggressive disease and worse prognosis 4

Thoracic Malignancies

• Malignant pleural mesothelioma (MPM): Typically highly FDG-avid, with degree of avidity indicating aggressiveness 5
• The nodular, rind-like morphology with thickness >1 cm helps differentiate MPM from benign tissue 5

Bone Tumors

• Osteosarcoma and Ewing sarcoma: FDG-avid, with uptake reflecting prognosis 6
• Bone metastases: Sensitivity 92%, specificity 98% for detection 7
• FDG PET-CT superior to bone scintigraphy for metastatic disease 4

Other Solid Tumors

• Soft-tissue sarcomas: FDG-avid, with SUVmax correlating with histologic aggressiveness 7
• Cholangiocarcinoma: FDG-avid 8
• Metastatic liver lesions: Accuracy 92-100% for detection 4

Moderately FDG-Avid Tumors

Gastric Cancer

• Approximately 90% of gastric cancers show FDG avidity 9
• 40% of associated lymph nodes are PET-avid 9
• Avidity independent of Lauren classification 9

Adrenal Lesions

• FDG-PET has 94% sensitivity and 82% specificity for characterizing adrenal nodules 4
• Lack of FDG uptake conclusively indicates benign adenoma 4

Mediastinal Masses

• High-risk thymomas, thymic carcinoma, and lymphoma: Higher SUVs than low-risk thymomas 2
• Normal and hyperplastic thymus can be FDG-avid, creating diagnostic confusion 2

Low or Variable FDG-Avid Tumors

Lung Cancer Subtypes

• Bronchoalveolar cell carcinomas: Little or no FDG uptake even when >1 cm 3
• Invasive mucinous adenocarcinoma (IMA):
  • Only 60.2% of solitary pulmonary nodule-type are FDG-avid 10
  • Non-FDG-avid IMA has significantly better prognosis 10

Gastrointestinal Tumors

• Mucinous adenocarcinomas: Notably lower FDG avidity 11
• Signet ring cell carcinomas: Lower FDG avidity 11

Hepatocellular Carcinoma (HCC)

• Variable FDG avidity, often less reliable than for other hepatic malignancies 8
• Well-differentiated HCC may show minimal uptake

Peritoneal Deposits

• Mucinous and signet ring subtypes: Lower FDG avidity noted on histological correlation 11
• Overall sensitivity 98.4% for peritoneal deposits, but specific subtypes show reduced uptake 11

Critical Technical Considerations

False-Positive FDG Uptake

• Inflammatory conditions: Infection, granulomatous disease (tuberculosis, sarcoidosis) 3, 7
• Post-procedural changes:
  • Talc pleurodesis causes indefinite FDG-avid inflammatory reaction 5
  • Wait 6-8 weeks post-surgery, 8-12 weeks post-radiation before restaging 5
• Physiologic uptake: Brown fat, skeletal muscle, healing fractures, fibrous dysplasia 7
• Benign lesions: >25% of oncologic PET-CT shows benign nonphysiologic FDG uptake 7

False-Negative Results

• Subcentimetric lesions: Critical mass of metabolically active cells required 3
• Specific histologic subtypes: As detailed above
• Timing issues: FDG-PET/CT should be performed within 60 days of planned resection, 30 days before radiation 4

Quantitative Thresholds

SUV Cutoff Values

• Peritoneal deposits: SUVmax threshold of 1.0 provides excellent discriminative power (AUC 0.915) 11
• Rib lesions: Best SUVmax cutoff of 2.4 for differentiating benign from metastatic (though accuracy only 57.2%) 7
• Soft-tissue sarcomas: SUVmax <10.2 associated with better event-free survival 7

Important Caveats

• No validated SUV threshold exists for thoracic lymph nodes 4
• SUV measurements depend on technical factors: uptake time, respiratory motion, scanner calibration 5
• Degree of FDG uptake does not necessarily reflect malignant potential in bone tumors 6

Clinical Algorithm for Interpretation

When evaluating FDG PET-CT findings:

1. Consider tumor histology first: Know which tumors characteristically show low avidity
2. Evaluate morphologic CT features: FDG uptake alone is inadequate for characterization 6
3. Account for timing: Recent surgery, radiation, or procedures cause inflammatory uptake
4. Apply appropriate SUV thresholds: Use validated cutoffs when available for specific tumor types
5. Confirm suspicious findings: Biopsy FDG-avid lesions when they represent the only site of potential metastatic disease 4